Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Beyond aleniglipron, Structure is also advancing two oral small-molecule amylin receptor agonists, ACCG-2671 and ACCG-3535, with potential as standalone treatments or as fixed-dose oral combinations
For type 2 diabetes, NICE guidance (NG28) recommends GLP-1 RAs based on individual factors including comorbidities, prior treatments, and HbA1c targets
More serious concerns include: Acute pancreatitis : If severe, persistent abdominal pain occurs, possibly radiating to the back, with or without vomiting, treatment should be discontinued immediately and urgent medical attention sought Gallbladder disease : GLP-1 medications and weight loss can increase the risk of gallstones and cholecystitis
Other GLP-1 receptor agonists, including Victoza (liraglutide) and Bydureon-BCise (exenatide), are available as once-daily injections for adolescents who have been diagnosed with type 2 diabetes
Supplied as a stable 10mg lyophilized vial
Disclosures The study was funded by Novo Nordisk
